A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. by Dickinson, L et al.
Contemporary Clinical Trials 36 (2013) 68–80
Contents lists available at SciVerse ScienceDirect
Contemporary Clinical Trials
j ourna l homepage: www.e lsev ie r .com/ locate /conc l in t r ia lAmulti-centre prospective development study evaluating focal
therapy using high intensity focused ultrasound for localised
prostate cancer: The INDEX study☆,☆☆L. Dickinson a,b,⁎, H.U. Ahmed a,b, A.P. Kirkham c, C. Allen c, A. Freeman d, J. Barber e,
R.G. Hindley f, T. Leslie g,h, C. Ogden i, R. Persad j, M.H. Winkler k,
M. Emberton a,b on behalf of the INDEX Study Group
a Division of Surgery and Interventional Sciences, University College London, UK
b Department of Urology, University College London Hospitals NHS Foundation Trust, UK
c Department of Radiology, University College London Hospitals NHS Foundation Trust, UK
d Department of Histopathology, University College London Hospitals NHS Foundation Trust, UK
e Department of Statistical Science, University College London, UK
f Department of Urology, Basingstoke and North Hampshire NHS Foundation Trust, UK
g Nufﬁeld Department of Surgical Sciences, Oxford University Hospitals, UK
h NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK
i Department of Urology, Royal Marsden NHS Foundation Trust, London, UK
j Department of Urology, University Hospitals Bristol NHS Foundation Trust, UK
k Department of Urology, Imperial College Healthcare NHS Trust, London, UKa r t i c l e i n f o☆ This is an open-access article distributed under
reproduction in any medium, provided the original au
☆☆ Funding: SonaCare Medical, LLC (previously kno
⁎ Corresponding author at: NIHR Academic Clinica
NW1 2PG, UK. Tel.: +44 203 4479194; fax: +44 203
E-mail address: Louise.Dickinson@uclh.nhs.uk (L.
1551-7144/$ – see front matter © 2013 The Authors.
http://dx.doi.org/10.1016/j.cct.2013.06.005a b s t r a c tArticle history:
Received 19 April 2013
Received in revised form 5 June 2013
Accepted 8 June 2013
Available online 14 June 2013Introduction: Focal therapy offers the possibility of cancer control, without the side effect
profile of radical therapies. Early single centre prospective development studies using high
intensity focused ultrasound (HIFU) have demonstrated encouraging genitourinary functional
preservation and short-term cancer control. Large multi-centre trials are required to evaluate
medium-term cancer control and reproduce functional recovery. We describe the study design
of an investigator-led UK multi-centre, single arm trial using HIFU to deliver focal therapy for
men with localised prostate cancer.
Methods: One-hundred and forty men with histologically proven localised low or intermediate
risk prostate cancer (PSA b 15, Gleason ≤7, ≤T2cN0M0) will undergo precise characterisation
of the prostate using a combination of multi-parametric (mp)MRI and transperineal template
prostate mapping (TPM) biopsies. Unilateral dominant tumours, the so-called index lesion,
will be eligible for treatment provided the contra-lateral side is free of ‘clinically significant’
disease (as defined by Gleason ≥7 or maximum cancer core length ≥4 mm). Patients will
receive focal therapy using HIFU (Sonablate 500®). Treatment effect will be assessed by
targeted biopsies of the treated area and TPM biopsies at 36-months.
Results: Primary outcome is the absence of clinically significant disease based on 36-month
post-treatment TPM biopsies. Secondary outcomes address a) genitourinary function using
validated patient questionnaires (IPSS, IPSS-QoL, IIEF-15, EPIC-Urinary, EPIC-Bowel, FACT-P,
EQ-5D), b) the predictive validity of imaging, and c) risk factors for treatment failure.Keywords:
Focal therapy
High-intensity focused ultrasound
Multi-centre
Prospective study
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69L. Dickinson et al. / Contemporary Clinical Trials 36 (2013) 68–80Conclusions: INDEX will be the first multi-centre, medium term follow-up trial to evaluate the
outcomes of a tissue preserving strategy for men with localised prostate cancer using the
TPM-ablate-TPM strategy.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction clinical trial guidelines for evaluation of a surgical interventionFocal or tissue-preserving therapy is a strategy that offers
men the potential for treating their localised prostate cancer
with a lower side-effect profile [1–4]. At present, men can
expect 30–90% erectile dysfunction, 5–20% incontinence and
5–20% rectal toxicity from radical prostatectomy or radiother-
apy [5–7]. These over-treatment harms may not be acceptable
in light of the small treatment benefit that can be derived
[8–10]. Early results from a number of small single centre
studies evaluating focal therapy have reported urinary incon-
tinence in about 1% and erectile dysfunction in 5–10% of men
with good baseline function [2,3,11].
However, these results have limited external validity since
they may be the product of careful patient selection, expert
treatment in specialist centres, and surrogate outcomes derived
over a short time-frame [12]. The next phase of development
therefore requires evaluation of this complex intervention
within a multi-centre setting, with longer follow-up, and with
primary outcomes based on disease control.
Although this is a laudable aim, there are difficulties in
designing a trial to evaluate outcomes on disease control. Firstly,
prostate cancer has a prolonged natural history. If overall and
disease-specific mortality were used as primary outcomes, for
instance, this would require hundreds of patients recruited over
many years and followed for at least 10–15 years to obtain any
degree of precision. Secondly, asmulti-focal disease is present in
most cases of prostate cancer, focal therapy inherently involves
ablation of only the dominant area, leaving behind tissue that is
likely to harbour prostate cancer lesions. Benign tissue may
also be predisposed to develop lesions de novo through a field
effect. Measuring rates of progression of untreated tissue
requires novel approaches. Thirdly, there exists no consensus
on the optimal medium term endpoints in tissue preserving
therapy since those surrogate measures used in radical whole-
gland therapies, which are primarily serum prostate specific
antigen (PSA) based, cannot be readily translated to a treat-
ment paradigm in which 50% or more of the prostate tissue is
still present [13,14]. Indeed, the FDA in the US has failed to
devise a regulatory pathway for this increasingly adopted form
of treatment.
The design of INDEX was informed by the reports of earlier
registered studies (NCT00561314, NCT00561262) that evalu-
ated different approaches to focal therapy, and from a number
of pivotal consensus meetings and processes [15–17]. This
report constitutes the next phase of the IDEAL development
pathway of a surgical intervention [18] and the MRC (UK)
guidelines [19] on evaluating a complex intervention.
2. INDEX study protocol
2.1. Study management
INDEX is a prospective, multi-centre, single-arm, therapeu-
tic, investigator-led study, conforming to Stage 2B of the IDEAL[18]. It is sponsored by University College London, with com-
mercial support from SonaCare Medical LLC (Charlotte, North
Carolina, USA), distributors of the Sonablate 500® device, for
infra-structural study costs (such as study personnel, transport
of device, trial meetings) through an unrestricted grant made
to UCL. The trial protocol was designed by investigators from
University College London, with input from external peer
reviewers and patient representatives, and conducted accord-
ing to Good Clinical Practice (GCP) guidelines. Monitoring of
subject safety and study compliance is being managed by Data
Monitoring and Trial Steering Committees, comprising an
impartial (medically qualified) chairperson, the co-chief in-
vestigators, study coordinator, principal investigators fromeach
study site, study statistician, and two patient representatives.
2.2. Study population
Since June 2011, INDEX has been recruiting men with his-
tologically confirmed, localised low or intermediate risk pros-
tate cancer (PSA b 15, Gleason≤7,≤T2cN0M0) on transrectal
ultrasound guided (TRUS) biopsies or template prostate map-
ping (TPM) biopsies (using a 5 mmsampling frame), whohave
not previously undergone treatment. The recruiting centres are
University College London NHS Foundation Trust (sponsor
centre), Hampshire Hospitals NHS Foundation Trust, Imperial
College Healthcare NHS Trust, Oxford University Hospitals NHS
Trust, Royal Marsden NHS Foundation Trust, and University
Hospitals Bristol NHS Foundation Trust.
2.3. Eligibility
Men are considered eligible for the trial if they have
unilateral or bilateral disease on TRUS biopsy, with amaximum
3 mm Gleason 3 + 3 disease on the non-dominant side, and/
or either unilateral disease or bilateral disease on TPM with no
more than clinically insignificant disease on the non-dominant
side (i.e. outside of the planned treatment area). Men recruited
following diagnostic TRUS biopsy undergo mpMRI and TPM
prior to focal HIFU treatment, to accurately map and locate
disease, and to ensure eligibility. Men can also be recruited and
proceed straight to focal HIFU treatment if they have already
undergone mpMRI and TPM that conform to the INDEX stan-
dards of conduct and reporting (Fig. 1). Full eligibility criteria
are detailed in Appendix A.
2.4. Study design
2.4.1. Trial entry
Eligible men are offered a patient information sheet, and
are invited to attend a screening visit. Those meeting inclusion
and exclusion criteria are fully counselled to their treatment
Fig. 1. Trial flow.
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part of the UK multidisciplinary approach to cancer manage-
ment. Validated patient questionnaires (International Prostate
Symptom Score (IPSS), International Prostate Symptom Score-
Quality of Life (IPSS QoL), International Index of Erectile
Function-15 (IIEF-15), UCLA Expanded Prostate Cancer Index
Composite (EPIC) urinary and bowel domains, EQ-5D Quality
of Life, Functional Assessment of Cancer Therapy (FACT)-
Prostate, and Memorial Anxiety Scale for Prostate Cancer) are
completed at baseline. Serum blood tests including PSA, renal
function, full blood count, and any other tests required to assess
fitness for general anaesthetic are performed. Patients are also
asked to consent (optional) to additional urine and blood
samples for the purpose of biobanking in order to develop and
validate novel biomarkers. Those consenting are asked to pro-
vide samples at baseline, 12 months and 36 months (Fig. 2).
The translational objectives of these research samples are
subject to planned academic collaborations, study protocols,
and ethics approvals.
2.4.2. Disease localisation
There is lack of consensus on the optimal strategy used to
localise individual lesions of cancer. Both mpMRI and TPMhave been proposed individually, and in combination.
State-of-the-art mpMRI has a very high negative predictive
value (in the order of 95%) for clinically significant disease
[20–22] and therefore could be used to determine which
areas of prostate do not undergo treatment. However, there
is an additional requirement for histological verification of
both the dominant lesion (since the positive predictive value
for mpMRI is at present not high) and absence of clinically
significant disease (as defined by Gleason ≥7 or maximum
cancer core length ≥4 mm) in the untreated area. As a
result, INDEX will use both tests in combination.
2.4.2.1. Imaging. Staging investigations follow local cancer
network guidelines. Multi-parametric MRI is performed prior
to TPM biopsies, and at least 6 weeks after any previous
diagnostic biopsy, in order to limit biopsy artefact that may
affect image interpretation. Pre-operative, and all post-HIFU,
imaging is performed using either a 1.5 Tesla or 3 Tesla MR
scanner, and a pelvic phased array receiver, with a pelvic coil.
A full protocol of T1 and T2 weighted turbo-spin echo images
and a dynamic post gadolinium volume acquisition is used
for both pre-operative diagnostic and planning scans and
post-operative assessment of focal treatment effect. The
Fig. 2. Imaging and pathological databanks.
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scoring system is used to report the probability of malig-
nancy from the images (Appendix B.2), as described from a
European consensus meeting on prostate mpMRI [23,24]. The
results are conveyed in diagrammatic, number and written
form using a standardised proforma. The prostate is divided
into 27 Regions of Interest for scoring. An example reporting
form is provided in Appendix B.3.
2.4.2.2. TPM biopsies. The process by which the specified
distribution of cancer is verified is primarily on transperineal
template 5 mm spaced prostate mapping biopsies. Biopsies
are taken every 5 mm from the prostate using a brachyther-
apy grid placed over the perineal skin, with the patient in the
lithotomy position. The number of biopsies is otherwise not
defined, and is dependent on prostate size. 3-Dimensionaldata on the location and specific grade for each focus of
cancer is produced within pictorial (Fig. 3) and written
reports and focal ablation planning based on this information.
TPM biopsies have a high accuracy for clinically significant
lesions with 95% sensitivity and 95% negative predictive value
for those lesions of 0.5 cm3 or greater in volume [25,26].
2.4.3. Focal therapy intervention
2.4.3.1. Ablativemodality.HIFUworks by focusing and depositing
a large pulse of high-energy ultrasonic waves on a single
area, thereby increasing the temperature to a point whereby
it causes coagulative necrosis. Focused ultrasound waves are
emitted from a transducer and are absorbed in the target
area of approximately 3 × 3 × 10 mm of tissue. The result is
a targeted thermal effect with minimal, or no, damage to the
tissue in the path of the ultrasound beam [27]. Two com-
mercially available devices exist for HIFU therapy: Ablatherm
(Edap Technomed, Vaulx-en-Velin, France) and Sonablate
500® (Focus Surgery, Indianapolis, IN, USA). This study uses
the Sonablate 500® device, which has a therapy-imaging
transducer with different focal lengths, and user-dependent
delivery of treatment according to live ultrasound images,
allowing precise control of energy delivery by each pulse. Our
reason for choosing this device is due to prior expertise
developed in its use for whole-gland ablation of the prostate
[28].
2.4.3.2. Treatment protocol. HIFU treatment is performed as a
day-case procedure, unless travel distance or co-morbidities
indicate an overnight stay, under general or regional anaes-
thesia. A transrectal resection of the prostate (TURP) is not
required prior to treatment, although permitted if performed
at least 6-months prior to study recruitment. A suprapubic
catheter is inserted under cystoscopic guidance prior to
treatment, or a urethral catheter at the end of treatment
if supra-pubic insertion is contra-indicated. A suprapubic
catheter has previously been shown by our group at UCLH
to reduce urethral stricture rates [28]. Patients are dis-
charged with the suprapubic catheter on free drainage for
24–48 h, with a planned trial without catheter between 5
and 14 days post-operatively. They are prescribed simple
analgesia (Diclofenac or Co-dydramol), laxatives, and a short
course of quinolone antibiotics (ciprofloxacin) at the clinician's
discretion.
The treatment is delivered to the hemi-gland (left or
right) in which the index lesion(s) has been identified by a
combination of mpMRI and TPM biopsy (Fig. 4). Treatment
can extend posteriorly or anteriorly over the midline, if
required, up to a maximum of 60% tissue ablation, and is
standardised to a hemi- or extended hemi-ablation in
centres with surgeons that have performed fewer than 20
cases independently, in order to standardise delivery during
the learning curve stage. Experienced centres may ablate a
quadrant. Treatment is planned to reach the urethra and
may cross the midline by up to 5–10 mm if the disease is
close to, or crosses, the midline. At least one neurovascular
bundle is avoided by ensuring a minimum distance of
ablation zone of 10 mm. One redo-HIFU to the treated side
is permissible, as per current protocols and standard practice
Fig. 3. Transperineal template mapping biopsy reporting protocol.
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side or ‘for-cause’ biopsies are positive, up until trial exit at
36-months.
2.5. Follow-up visits
Trial clinic visits (telephone or clinic consultation) occur
at 6 weeks, 3, 6, 9, 12, 18, 24, 30 and 36 months. At each visit
data is collected on adverse events, patient questionnaires,
and serum PSA levels. An early contrast-enhanced MRI is
performed at 1–3 weeks post focal HIFU to verify that the
treatment has been delivered appropriately according to plan
as well as to determine whether adequate energy has been
delivered. It is carried out in the first 5 patients per centre (at
least) as a quality control measure as it shows areas of
perfusion deficits that usually correlate well with the quality
of treatment delivery [29].Men receive further mpMRIs (as per pre-HIFU protocol) at
12 and 36-months. Targeted biopsies are taken at 12-months
under local anaesthetic, using the transrectal or transperineal
route, as per clinician's discretion. These are of the treated
area only in order to assess treatment success, with a mini-
mum of 1 biopsy per 1–2 ml of prostate volume. Biopsy of the
untreated area is only carried out if a new suspicious lesion is
detected on the 12-month mpMRI, which was not present in
that area on the pre-treatment mpMRI. This limited biopsy
protocol is carried out in order to minimise burden on the
patient, especially as a full mapping had been conducted only
12 months prior to this, and it would be rare for any untreated
tissue to progress within such a timeframe. At 36-months, a
further TPM is carried out of all residual tissue, and reported
in the same format as the pre-treatment template biopsies in
order to measure progression, if any. Areas that are absent
within the 20-zone protocol are omitted.
Fig. 4. Treatment protocol.
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Clinicians can biopsy the prostate between primary focal
HIFU and 36 months if there is a clinically significant rise in
PSA (‘for cause’ biopsy) following consensus approval by a
Study Investigators Group. In the event of apparent significant
under-treatment on early mpMRI, an additional ‘for-cause’mpMRI may be performed a minimum of 6-months following
HIFU, at the discretion of the Study Investigators Group. This is
the first time-point at which prostatic inflammation is ex-
pected to have diminished sufficiently to detect any foci of
residual disease, potentially warranting ‘for-cause’ biopsy.
Other ‘for cause’ additional tests such as ultrasound, mpMRI,
74 L. Dickinson et al. / Contemporary Clinical Trials 36 (2013) 68–80CT scan, bone scan or PET scan are permissible as per local
centre practice.
2.6. Objectives
There are two co-primary objectives of INDEX for cancer
control on the 36-month TPM. The first is to determine the
proportion of men who are free of any prostate cancer in the
treated area and are free of clinically significant prostate
cancer in the untreated area 36 months after focal therapy
using HIFU. The second is to determine the proportion of men
who are free of clinically significant prostate cancer in the
treated area and are free of clinically significant prostate
cancer in the untreated area 36 months after focal therapy
using HIFU.
Secondary objectives include an assessment of interim
cancer control at 12 months as assessed on targeted biopsy of
the treated area, short to medium-term functional (sexual,
urinary, bowel) and quality of life outcomes, the rate of sec-
ondary prostate cancer intervention (prostatectomy, radio-
therapy, androgen ablation, whole-gland HIFU or cryosurgery),
and an assessment of biochemical (PSA) kinetics, following
focal HIFU. Risk factors for failure to achieve the co-primary
objectives will be analysed. Finally, an assessment of the
clinical validity (sensitivity, specificity, negative and positive
predictive values, inter-observer variability) will be made of
the mpMRI imaging technique both to identify the presence of
clinically significant prostate cancer on TPM biopsies prior to
focal therapy, and the presence of residual/recurrent clinically
significant prostate cancer on post-HIFU (12-month and
36-month) biopsies.
At the lead centre only (University College London Hospital),
an additional nested pilot study has been performed in the first
26 patients treated with an MR-visible lesion, on the safety and
feasibility of a novel MR-TRUS registration system for planning
and conducting focal treatment of prostate cancer [30]. The
MR-US registration system has previously been described by
Hu et al. [31,32]. The secondary objectives of this pilot study
were to determine the number of patients in whom the
planned treatment volume was increased as a result of
MR-US image registration, the volume change between initial
and registration-informed treatment plans, the time required
to plan the treatment manually versus registration-based
planning alone or a combination of the two methods, and the
volume overlap between target volumes, as defined by the
HIFU treatment plan, and the regions of necrosis visible in
post-operative MR images. Full results of this pilot study have
been recently published elsewhere [30].
Pending financial resources, we aim to determine the costs
of focal treatment, with modelling of potential cost effective-
ness using existing datasets of cancer control and functional
outcomes at 36 months achieved by radical whole-gland
therapies and active surveillance.
2.7. Training/quality control protocol
The success or otherwise of a new intervention is heavily
dependent on training and quality control of new users. This
needs to be both comprehensive and flexible, to fit in with
clinical practice. With these factors in mind a pragmatic, but
nonetheless robust, clinical training programme has beendrawn up for the purpose of delivering the interventions
within this trial. Only clinicians attending the training sessions
(or another equivalent training programme) are approved as
reporters or surgeons within the study.2.7.1. Multi-parametric MRI
A nominated consultant radiologist attended the lead
centre for a training day on the conduct and reporting of pre-
and post-treatment (early and late) mpMRI prior to the study
commencing. The mpMRI from the first 5 patients are double
reported by a radiologist expert in prostate MRI as a quality
control measure. Discrepancies are dealt with by an arbitrat-
ing third radiologist, expert in prostate MRI.2.7.2. TPM biopsies
All clinicians carrying out TPM biopsies are required to
carry out TPM biopsies to protocol standard. Each clinician is
required to observe a minimum of two TPM biopsies at an
expert centre. Each clinician will then be proctored for the
first two cases by an approved expert proctor, with the
period of proctoring extended at the discretion of the proctor.2.7.3. TRUS guided biopsy
There is no formalised specific training programme for
clinicians carrying out TRUS biopsies but all clinicians are
required to conduct the targeted TRUS biopsies after focal
therapy as laid down by the trial protocol.2.7.4. Pathology
A specialist pathology meeting was held prior to trial
commencement, for nominated prostate histopathologists
with expertise in uropathology, where the requirements for
standardised pathology reporting were discussed. All study
pathologists are required to report the biopsies as laid down
by the trial protocol.2.7.5. Focal HIFU
Clinicians undergo training and proctoring to ensure
treatment is delivered to a standard laid down by the lead
centre. Clinicians with or without previous HIFU experience
are required to visit an expert training centre on at least two
occasions and observe at least three cases of focal HIFU.
Clinicians with previous HIFU experience are required to un-
dergo proctoring for at least their first 5 cases on any number of
visits, with extension at the discretion of the proctor. Clinicians
with no previous HIFU experience are required to undergo
proctoring for their first ten cases on any number of visits, with
extension at the discretion of the proctor. Clinicians are signed
off for non-proctored cases once the first 10 or 20 cases for
that clinician has undergone review, including against post-
treatment early contrast MRI. Only approved clinicians deliver
the treatment within this trial. Only one clinician per site is
proctored until competent to perform focal HIFU independent-
ly. Each trial centre is required to treat at least 5 patients within
the trial period to ensure that the required HIFU treatment
skills are maintained. Any re-do focal HIFU treatments per-
formedwithin the trial periodwill be proctored with an expert
proctor and/or HIFU technician present.
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2.8.1. Sample size calculation
The primary objective is to estimate the proportion of
men who are free of any prostate cancer in the treated area
and are free of clinically significant prostate cancer in the
untreated area 36 months after focal therapy using HIFU. The
second is to determine the proportion of men who are free of
clinically significant prostate cancer in the treated area and
are free of clinically significant prostate cancer in the untreated
area 36 months after focal therapy using HIFU. Evidence from a
small single centre trial at UCLH demonstrated that event rates
could be as high as 100% absence of clinically significant cancer
and 90% absence of any cancer in the treated areas at 6 months
following focal therapy [2]. Clinical knowledge indicates that
these rates are likely to be lower in a multi-centre trial with
further follow up. In calculating sample size for the current
study we therefore assumed 90% of patients will have no
evidence of clinically significant cancer at 36 months and 80%
will have no evidence of any cancer at 36 months in the treated
area. Using a precision-based calculation for 95% confidence
intervals we calculated that at least a sample size of 140
patients would be needed to estimate these proportions to
within 7% (including an inflation for 10% dropout) [33].
2.8.2. Primary outcomes
The proportion of patients with evidence of clinically
significant prostate cancer at 36 months and those with no
evidence of cancer at 36 months (in the treated areas as per
the outcome definitions above) will be estimated along with
associated 95% confidence intervals.
2.8.3. Secondary outcomes
Secondary outcomes will be reported as estimates with
95% confidence intervals calculated using standard statistical
methods as appropriate for the type of outcome. For patient
reported outcomes with available baseline measurements,
comparison will be made with baseline values using paired
analyses. Logistic regression will be used to investigate asso-
ciations with potential risk factors for histological failure,
considering PSA, Gleason score, cancer core length involve-
ment (mm and %), number and % of positive biopsies for any
cancer on TPM and TRUS, stage and D'Amico risk group (low,
intermediate, high). Sensitivity and specificity (with 95%
confidence intervals) will be estimated in considering the
use of standard PSA kinetics and thresholds for identifying
clinically significant cancer. Modelling methods for serial
measurements will be used to consider patterns of PSA change
associated with subsequent positive biopsy.
3. Discussion
3.1. Summary of protocol
The INDEX trial will be the first prospective study testing
focal therapy with HIFU within a multi-centre setting, with
medium-term quality of life and histological outcomes. The
safety and tolerability of focal HIFUwithin single centre studiesare already known [2,3]. These demonstrate a very low event
rate for both erectile dysfunction and incontinence, and en-
couraging cancer control, over a 12-month follow-up period. It
follows that INDEX should be the next step within a phased
development and evaluation programme.
We have used a pragmatic trial design, to include men
with a range of baseline functional status. Furthermore, we
have included men with unilateral/unifocal disease and those
with multi-focal disease with treatment targeted to the index
lesion. There is a new body of evidence emerging demon-
strating that the index lesion usually harbours the highest
Gleason pattern, and is responsible for disease progression
[34–39]. There have been recent calls to re-assign low
volume low grade lesions as something other than cancer in
order to reflect their indolent nature [40–42]. INDEX follows
a ‘template–focal treatment–template’ protocol, ensuring
highly accurate histological planning and follow-up. This is
the first prospective study, to the best of our knowledge,
which incorporates 5 mm transperineal template mapping
biopsy at study entry and study exit, providing a unique
histopathological dataset and the means for interrogating the
natural behaviour of untreated benign tissue and clinically
insignificant disease [43].
INDEX may also confirm that focal therapy can lead to
low rates of genitourinary and rectal toxicity and minimal
impact on quality of life within a large and more represen-
tative cohort of patients than in previously described studies.
Further, an important step in the dissemination of a new
technique is the transfer of skills within a safe and controlled
environment. INDEX aims to demonstrate that the diagnostic
and therapeutic skills acquired by one research centre are
transferable to others. Finally, we aim to estimate costs of
care and to model potential cost-effectiveness in comparison
to alternative ‘standard’ therapies. If this single arm inter-
vention study demonstrates acceptable outcomes supporting
the findings of the early short-term studies it could lead onto
a randomised controlled trial, prior to more widespread use
of this technology.
3.2. Limitations
The first limitation relates to study design. Verification of
a new therapy as favourable, or equivalent, to ‘standard’ care
is ideally sought through comparison with another matched
control group. Randomised controlled trials (RCTs) offer
the best method for minimising systematic bias and revealing
the true effect of an intervention or drug. However, RCTs
involving treatments of localised prostate cancer have had a
historically poor patient uptake, as the reference ‘gold’ stan-
dard of care is not known. In addition, RCTs are expensive to
run and involve huge infra-structural support. A number of
trials have been forced to close due to lack of recruitment
[44–55]. A randomised trial may be feasible if a pragmatic
design is adopted, but prior to acceptance of such a design,
the number of centres with expertise in this complex inter-
vention (mpMRI, TPM, focal HIFU) needs to be increased.
Observational studies, such as INDEX, are a commonly used
alternative to ascertain the effectiveness of a treatment. They
are used to observe a treatment effect in a selected group
of patients who are presumed to derive benefit from the
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and therefore prone to bias, they have some benefits over
RCTs. The principal ones are those of enhanced external
validity (many patients do not wish to be randomised and
therefore refuse participation in RCTs), and more rapid
accrual compared to a randomised design. For these reasons,
INDEX was designed as a single arm medium term follow-up
cohort intervention study, although we acknowledge that it
should ultimately lead onto an RCT of focal therapy against
‘standard care’.
Another limitation of INDEX relates to the use of surrogate
outcome measures. There are currently no validated or
agreed outcome measure other than prostate cancer related
deaths or rate of metastatic disease that serve as a mean-
ingful clinical outcome measure across the prostate cancer
therapies, including focal therapy. However, in a focal
therapy trial with a very low expected rate of death and
metastatic progression in a sub-set of low-intermediate risk
patients, some 10–15 years would have to pass after treat-
ment before sufficient events were accrued in order to gain
meaningful results on which to base the outcomes of this
therapy. Furthermore, a trial would require 2000–3000
patients. We have therefore had to adopt surrogate second-
ary outcome measures of outcome. We are exploring four
main outcome categories in this study that we believe will
provide optimal and appropriate information at this stage of
evaluation of an innovative technique, although all aspects
carry some limitations. Firstly, treatment related side-effects
will be relatively well captured using validated question-
naires. In focal therapy studies reported to date, stability in
terms of functional health status is achieved between 3 and
6 months following the intervention. This domain of out-
come will therefore be derived relatively early. The second
relates to a more global assessment of quality of life. We are
using some tools that are generic, and some designed spe-
cifically for the evaluation of patients with prostate cancer.
The third, and most problematic area, relates to the type and
timing of the surrogate cancer related outcomes used (PSA,
biopsy, imaging, additional therapy). This problem arises
since radical therapies use very different outcome measures
based on PSA kinetics with little consensus across different
modalities of treatment. No such outcome measures have yet
been validated for focal therapies. Indeed, focal therapy is
further problematic in this respect as tissue is left untreated,
and this tissue will inevitably give rise to PSA increases with
time. The fourth relates to the costs of care and incorporates
cost-effectiveness, cost utility and cost benefit. Apart from
cost minimization exercises nested on the intervention
versus known costs of alternative intervention, most eco-
nomic analyses will require that cancer outcomes are derived
as well as functional status and quality of life. We are collab-
orating with health economic experts and lead clinicians in
this field with the aim of exploring this.
3.3. Expected time-frame for results
The first patient was recruited to the INDEX study in June
2011 and received focal HIFU treatment in July 2011. All 6
study centres were actively recruiting patients fromMay 2012.
Recruitment rates have been achieved at the expected accrualrate, and the study is expected to continue recruitment until
the third quarter of 2013, with the planned study number of
154 men treated expected by the end of 2013.4. Conclusions
INDEX will test focal therapy within a multi-centre setting,
using robust quality control processes to ensure interventions
are delivered to a uniform standard. The protocol offers an
opportunity to evaluate the natural history of untreated
low-grade, low-volume prostate cancer lesions and the index
lesion hypothesis. Further, there is a unique opportunity to
validate novel imaging and tissue biomarkers as predictors of
outcome. It is hoped that the outcomes of this studywill lead to
further evaluation of focal therapy within a randomised com-
parative setting prior to widespread dissemination of this
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A.1. Inclusion criteria
The population studied will be those patients who have:
• Histologically proven prostate cancer on trans-rectal or
transperineal template prostate biopsies
• TRUS biopsy: up to burden bilateral disease with maximum
3 mm one biopsy on non-dominant side is allowable.
• Template biopsy:
– unilateral disease any burden
– bilateral disease
the presence of clinically significant cancer on only one
side (as determined by histological rules described above)
Gleason ≤7, or
clinically insignificant disease with a burden of >50% of
biopsy cores taken on that side, or
bilateral clinically insignificant disease and b50% of biopsy
cores positive on any one side but with dominant disease
burden on one side• Stage T1-T2cN0M0 disease, as determined by local guide-
lines (radiological T3a permitted)
• Serum PSA ≤15
• Life expectancy of ≥10 years
• Signed informed consent by patient
• An understanding of the English language sufficient to
understand written and verbal information about the trial
and consent process.
A.2. Exclusion criteria
• Men who have had previous radiation therapy
• Men who have had androgen suppression/hormone treat-
ment within the previous 12 months for their prostate
cancer
• Men with evidence of metastatic disease or nodal disease
outside the prostate on bone scan or cross-sectional
imaging
• Men with an inability to tolerate a transrectal ultrasound
• Men with latex allergies as the HIFU probe is covered with
a latex condom sheath prior to insertion into the back
passage
• Men who have undergone prior significant rectal surgery
preventing insertion of trans-rectal HIFU probe (decided on
the type of surgery in individual cases)
• Men who have had previous HIFU, cryosurgery, thermal or
microwave therapy to the prostate.
• Men who have undergone a transurethral resection of the
prostate (TURP) for symptomatic lower urinary tract symp-
toms within 6 months. These patients may be included
within the trial if deferred from consenting and screening
until at least 6 months following the TURP.
• Men not fit for major surgery as assessed by a Consultant
Anaesthetist
• Men unable to have pelvic MRI scanning (severe claustro-
phobia, permanent cardiac pacemaker, metallic implant
etc. likely to contribute significant artefact to images)
• The presence of metal implants/stents in the urethra• The presence of prostatic calcification and cysts (on transrectal
ultrasound) whose location will interfere with effective de-
livery of HIFU therapy
• Men with renal impairment with a GFR of b35 ml/min
(unable to tolerate gadolinium dynamic contrast enhanced
MRI).Appendix B. MRI protocol
B.1. MRI conduct
B.1.1. General guidelines
a) A standard safety questionnaire should be completed.
b) For contrast enhancement: set up IV line in a vein in the
antecubital fossa, connected to an automated injector with
two syringes (contrast and saline flush).
c) 20 mg buscopan or 1 mg glucagon iv are optional, depend-
ing on local practice.
d) T2 sequences:
Small field of view in 3 planes. The fields of view provided
on the standard sequences are enough to cover most pros-
tates. However, if the tips of seminal vesicles and the
external sphincter cannot be included on the axial sequence,
the number of slices (and with it the scan time) should be
increased. In all cases the slice width should remain at
3 mm, with a 10% interslice gap.
e) Diffusion sequences (not included on early post HIFU
scan):
i) Multi-b with b values of 0,100,500 and 1000 s/mm2. 16
averages using a 3-trace technique. Standard Siemens
algorithm for determination of ADC (currently includes
b0 with monoexponential decay fitting, but this may be
revised)
ii) b1400 s/mm2 with 32 averages.
f) VIBE sequences:Dynamic contrast enhancement. Coverage should include
the external sphincter and seminal vesicles as for the T2 axial
sequences. If this cannot be ensured, the priority is to include
the prostatic apex: the seminal vesicle tips are less important,
as long as most of the vesicles are included. Contrast is
0.1 mmol/kg of low molecular weight gadolinium-based
contrast: Magnevist or Dotarem (preferred in those with
mild renal impairment), given at 3 ml/s. This should be
followed by a flush of 20 ml normal saline. The infusion is
started concurrently with the third dynamic acquisition.
Acquisitions are continued for at least 5 min and 30 s after
the start of the contrast infusion.
B.2. 5-Point Likert-type scoring system for mpMRI reporting
1 highly likely benign
2 likely benign
3 equivocal
4 likely malignant
5 highly likely malignant.
B.3 Example mpMRI reporting form (pre-HIFU)
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